MARKET

BPMC

BPMC

Blueprint Medicines Corp
NASDAQ
95.81
+1.02
+1.08%
Opening 15:13 03/28 EDT
OPEN
95.00
PREV CLOSE
94.79
HIGH
95.98
LOW
93.75
VOLUME
319.34K
TURNOVER
0
52 WEEK HIGH
101.00
52 WEEK LOW
41.54
MARKET CAP
5.87B
P/E (TTM)
-11.4442
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BPMC last week (0318-0322)?
Weekly Report · 3d ago
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
NASDAQ · 03/21 15:30
Weekly Report: what happened at BPMC last week (0311-0315)?
Weekly Report · 03/18 09:28
Despite shrinking by US$265m in the past week, Blueprint Medicines (NASDAQ:BPMC) shareholders are still up 95% over 1 year
The Blueprint Medicines Corporation (NASDAQ:BPMC) share price is 95% higher than it was a year ago. The company grew its revenue by 22% last year. The share price has gained 95% over the last 12 months, better than the market return of 28%. The stock has fallen 11% in the last three years. But the company may not be the best stock to buy.
Simply Wall St · 03/15 10:28
Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
NASDAQ · 03/12 12:03
Weekly Report: what happened at BPMC last week (0304-0308)?
Weekly Report · 03/11 09:27
Blueprint Medicines Corp: Statement of changes in beneficial ownership of securities
Press release · 03/07 06:02
Wells Fargo screens for momentum names to play and contrarian plays to avoid
Wells Fargo's equity team says investors should resist the urge to bottom-fish. The recent dominance of momentum strategies should continue, the analysts say. The contrarian basket isn't compelling, they say. Wells Fargo screens for momentum names to play and contrarian plays to avoid.
Seeking Alpha · 03/04 15:02
More
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Webull offers Blueprint Medicines Corp stock information, including NASDAQ: BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.